Lamia Tazi, a leading Moroccan billionaire and CEO of Marocaine Ste de Therapeutique (Sothema), has seen the market value of her stake in Sothema fall significantly as a result of the healthcare group’s share price slump on the Casablanca exchange.
The market value of her share in Sothema has dropped by MAD36.3 million ($3.61 million) in the last nine days to MAD586.88 million ($58.34 million), owing to recent selling pressures on the Casablanca exchange.
Sothema is Morocco’s largest healthcare firm, generating around 60 million units of pharmaceuticals each year and managing a diverse portfolio of 35 global laboratories that manufacture and sell items to Europe, the Maghreb, Sub-Saharan Africa, and the Persian Gulf.
Since March 28, the company’s share price has dropped by 5.8 percent to MAD970 ($96.42) from MAD 1,030 ($102.38), resulting in a market cap of less than $700 million and huge losses for shareholders, including Lamia Tazi.
Tazi, Sothema’s CEO and chairperson, owns a hefty 8.4 percent stake in the major healthcare company, which translates to 605,030 issued shares. This has cemented her status as one of the wealthiest investors on the Casablanca Stock Exchange.
Tazi’s stake’s market value has dropped by MAD36.3 million ($3.61 million) over the last nine days, from MAD623.18 million ($61.95 million) on March 28 to MAD586.88 million ($58.34 million).
Despite a recent fall in her income, the Moroccan CEO remains among the most wealthy investors on the Casablanca exchange. She is ranked 52nd on Forbes’ 2024 list of the 100 Most Powerful Businesswomen in the Middle East.